Sarah R Vincze, Ambika P Jaswal, Stephen C Frederico, Michal Nisnboym, Bo Li, Zujian Xiong, ReidAnn E Sever, Chaim T Sneiderman, Mikayla Rodgers, Kathryn E Day, Joseph D Latoche, Lesley M Foley, T Kevin Hitchens, Robin Frederick, Ravi B Patel, Costas G Hadjipanayis, Itay Raphael, Jessie R Nedrow, W Barry Edwards, Gary Kohanbash
Glioblastoma (GBM) is the most common primary malignant brain tumor. Currently, there are few effective treatment options for GBM beyond surgery and chemo-radiation, and even with these interventions, median patient survival remains poor. While immune checkpoint inhibitors (ICIs) have demonstrated therapeutic efficacy against non-central nervous system cancers, ICI trials for GBM have typically had poor outcomes. TIGIT is an immune checkpoint receptor that is expressed on activated T-cells and has a role in the suppression of T-cell and Natural Killer (NK) cell function...
March 4, 2024: Scientific Reports